blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4146208

EP4146208 - TREATMENT OF VIRAL INFECTION, DISEASE OR DISORDER USING A SELECTIVE S1R AGONIST [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  10.02.2023
Database last updated on 15.06.2024
FormerThe international publication has been made
Status updated on  12.11.2021
Most recent event   Tooltip24.04.2024Supplementary search reportpublished on 22.05.2024  [2024/21]
Applicant(s)For all designated states
Prilenia Neurotherapeutics Ltd.
Yakum Greenwork Business Park
Mindspace Offices
Building D
6097200 Yakum / IL
[2023/11]
Inventor(s)01 / HAYDEN, Michael
6097200 Yakum / IL
02 / GEVA, Michal
405000 Even-Yehuda / IL
 [2023/11]
Representative(s)Pearl Cohen Zedek Latzer Baratz UK LLP
The Gridiron Building
One Pancras Square
London N1C 4AG / GB
[2023/11]
Application number, filing date21799724.604.05.2021
[2023/11]
WO2021IL50507
Priority number, dateUS202063019465P04.05.2020         Original published format: US 202063019465 P
[2023/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021224914
Date:11.11.2021
Language:EN
[2021/45]
Type: A1 Application with search report 
No.:EP4146208
Date:15.03.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 11.11.2021 takes the place of the publication of the European patent application.
[2023/11]
Search report(s)International search report - published on:IL11.11.2021
(Supplementary) European search report - dispatched on:EP23.04.2024
ClassificationIPC:A61K31/451, A61P31/12, A61P31/14
[2023/11]
CPC:
A61P31/12 (EP,IL); A61K31/451 (EP,IL,US); A61P31/14 (EP,IL,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/11]
TitleGerman:BEHANDLUNG VON VIRUSINFEKTIONEN, ERKRANKUNGEN ODER STÖRUNGEN UNTER VERWENDUNG EINES SELEKTIVEN S1R-AGONISTEN[2023/11]
English:TREATMENT OF VIRAL INFECTION, DISEASE OR DISORDER USING A SELECTIVE S1R AGONIST[2023/11]
French:TRAITEMENT D'UNE INFECTION VIRALE, D'UNE MALADIE OU D'UN TROUBLE À L'AIDE D'UN AGONISTE DE S1R SÉLECTIF[2023/11]
Entry into regional phase01.12.2022National basic fee paid 
01.12.2022Search fee paid 
01.12.2022Designation fee(s) paid 
01.12.2022Examination fee paid 
Examination procedure01.12.2022Examination requested  [2023/11]
13.06.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
01.12.2022Renewal fee patent year 03
13.03.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2012064654  (INHIBIKASE THERAPEUTICS INC [US], et al) [X] 1,2,4,9,10 * p. 15, l. 19-22; Fig. 4; ex. 1 + Fig. 3 *;
 [X]WO2016138135  (TEVA PHARMACEUTICALS INT GMBH [CH], et al) [X] 1,4,9,10 * claims 1, 4, example 6 *;
 [X]WO2018073549  (UNIV CLAUDE BERNARD LYON [FR], et al) [X] 1,2,4 * claims *;
 [E]WO2021195470  (VANDA PHARMACEUTICALS INC [US]) [E] 1-4,9,10 * claims, in particular cl. 27/28. *;
 [E]WO2021207300  (HISTA RX LLC [US]) [E] 1-4,9,10 * claims 6, 7;§§50-70 *;
 [I]  - SCHAFER ADAM ET AL, "Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, (20180704), vol. 157, doi:10.1016/J.ANTIVIRAL.2018.07.003, ISSN 0166-3542, pages 47 - 56, XP085439218 [I] 1,4,9 * title, abstract; tables 1+3; and Fig. 1 *

DOI:   http://dx.doi.org/10.1016/j.antiviral.2018.07.003
 [I]  - Smieszek Sandra P. ET AL, "Amantadine disruprs lysosomal gene expression; potential therapy for COVID19", bioRxiv, doi:10.1101/2020.04.05.026187, (20200405), pages 1 - 15, URL: https://www.biorxiv.org/content/10.1101/2020.04.05.026187v2.full.pdf, (20210804), XP055830056 [I] 1-5,9-11 * title, abstract; discussion *

DOI:   http://dx.doi.org/10.1101/2020.04.05.026187
 [I]  - LI XIANGQI ET AL, "Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, UNITED STATES, (20200430), vol. 34, no. 5, doi:10.1096/FJ.202000502, ISSN 1530-6860, pages 6008 - 6016, XP009526071 [I] 1-5,9-11 * title, abstract; p. 6009, last § of col. 1 to first § of col. 2 *

DOI:   http://dx.doi.org/10.1096/fj.202000502
 [A]  - MAURICE T ET AL, "The pharmacology of sigma-1 receptors", PHARMACOLOGY & THERAPEUTICS, ELSEVIER, GB, vol. 124, no. 2, doi:10.1016/J.PHARMTHERA.2009.07.001, ISSN 0163-7258, (20091101), pages 195 - 206, (20090718), XP026626456 [A] 1-14 * p. 200, section 1.9; p. 201, 2nd line of 3rd § of col. 1 *

DOI:   http://dx.doi.org/10.1016/j.pharmthera.2009.07.001
 [I]  - Clinicaltrials.Gov, "A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection", (20200413), pages 1 - 8, URL: https://clinicaltrials.gov/ct2/show/NCT04342663, (20220607), XP055928475 [I] 1-5,9-11 * the whole document *
 [A]  - Vahabzadeh Gelareh ET AL, "Noscapine Modulates Neuronal Response to Oxygen-glucose Deprivation/Reperfusion Injury Via Activation of Sigma-1 Receptor in Primary Cortical Cultures", Iranian journal of pharmaceutical research : IJPR, Tehran, Iran, doi:10.22037/ijpr.2019.112317.13683, (20200101), pages 331 - 342, URL: https://brieflands.com/articles/ijpr-124433.pdf, (20240326), XP093145985 [A] 1-5,9,10 * title, abstract *

DOI:   http://dx.doi.org/10.22037/ijpr.2019.112317.13683
 [AP]  - OSTROV DAVID A. ET AL, "Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells", PATHOGENS, (20211120), vol. 10, no. 11, doi:10.3390/pathogens10111514, ISSN 2076-0817, page 1514, XP093145989 [AP] 1-5,9,10 * title, abstract *

DOI:   http://dx.doi.org/10.3390/pathogens10111514
 [A]  - KULKARNI S K ET AL, "On the mechanism of antidepressant-like action of berberine chloride", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 589, no. 1-3, doi:10.1016/J.EJPHAR.2008.05.043, ISSN 0014-2999, (20080728), pages 163 - 172, (20080603), XP023179500 [A] 1-5,9-11 * title, abstract; p. 170, col. 2, penultimate § *

DOI:   http://dx.doi.org/10.1016/j.ejphar.2008.05.043
International search[A]US2015374677  (SCHMIDT MALLE [EE], et al) [A] 6-10,14-18,22-41 * Abstract, paragraphs [0004]-[0006], claims *;
 [A]AU2017315783  (PRILENIA NEUROTHERAPEUTICS LTD [IL]) [A] 1-41 * Abstract, page 2 first paragraph, page 98 lines 22-25, page 99 lines 11-22, page 100 first paragraph *;
 [A]  - GORDON DE et al., "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing", Nature, (20200430), vol. 583, no. 7816, doi:10.1038/s41586-020-2286-9, pages 459 - 468, XP037193974 [A] 1-41 * Abstract, page 461 left column, pages 466-467, fig. 6, extended data fig. 10 *

DOI:   http://dx.doi.org/10.1038/s41586-020-2286-9
 [A]  - MINAKSHI R et al., "The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of type 1 interferon recepto r", PLoS One, (20091217), vol. 4, no. 12, doi:10.1371/journal.pone.0008342, pages 1 - 10, XP055872015 [A] 1-41 * The whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0008342
 [A]  - Shafiul Alam, A. Wayne Orr, Christopher B. Pattillo ,Shenuarin Bhuiyan, "Abstract 281: Sigma-1 Receptor Dependent Pathway for a Protective Endoplasmic Reticulum Stress Response in Cardiomyocytes", Circulation research Grunde and stratton , Baltimore, US, US , (20170223), vol. 119, no. suppl._1, doi:10.1161/res.119.suppl_1.281, ISSN 0009-7330, page Abstract 281, XP009541185 [A] 1-41 * The whole document *

DOI:   http://dx.doi.org/10.1161/res.119.suppl_1.281
 [A]  - DRYDEN J, Study to evaluate antidepressant as potential COVID-19 treatment, St. Louis, (20200413), URL: https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment, (20210706), XP055872026 [A] 1-41 * The whole document *
 [PY]  - VELA JM, "Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?", Front Pharmacol, (20201109), vol. 11, no. 582310, doi:10.3389/fphar.2020.582310, pages 1 - 23, XP055860803 [PY] 1-41 * The whole document *

DOI:   http://dx.doi.org/10.3389/fphar.2020.582310
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.